GLP-1 inhibitors like Ozempic and Mounjaro are everywhere — but almost no one is talking about how they affect cancer metabolism.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, breaks down how GLP-1 drugs influence insulin, inflammation, mitochondrial health, and the metabolic pathways cancer depends on. You’ll learn how lowering sugar spikes, reducing visceral fat, and improving insulin sensitivity can help create a cancer-resistant terrain — and why precision oncology still requires addressing the mutational and immune sides of cancer.

Dr. Prato also explains natural, research-supported ways to boost GLP-1 activity without medication — including intermittent fasting, herbamate tea, resistant starches, allulose, fermented foods, mitochondrial support nutrients, and smart monitoring of glucose and insulin through wearables. He also warns where GLP-1 medications may pose additional risks, and why microdosing is the safest model when medically appropriate.

🎯 What You’ll Learn in This Episode:
• How GLP-1 drugs affect insulin, inflammation & cancer metabolism
• Why sugar and refined carbs accelerate cancer growth
• How intermittent fasting (16:8) boosts metabolic efficiency
• Natural GLP-1 boosters: herbamate, allulose & resistant starches
• Why insulin resistance is more important than LDL for metabolic cancer risk
• How mitochondrial nutrients (CoQ10, PQQ, electrolytes) increase cellular energy
• The pros & cons of GLP-1 medications — including risks for certain cancers
• How wearables (Oura, smartwatches) reveal your real-time glucose response

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493